Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's drug may impact gum disease risk

NCT ID NCT07405268

Knowledge-focused Sponsor: Saglik Bilimleri Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study looks at whether the Parkinson's drug Levodopa-Benserazide affects gum health and inflammation. Researchers will measure gum health and saliva markers in 136 people, including Parkinson's patients with and without gum disease, and healthy controls. The goal is to understand how this common medication might influence oral health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levodopa-Benserazide
What this could lead to
If successful, this could help doctors understand how Parkinson's medication affects gum health, potentially leading to better dental care for patients.
What could go wrong
This is a small, observational study that only measures markers, not a treatment trial. Results may not apply to all Parkinson's patients or lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from the Department of Neurology at Hacettepe University Faculty of Medicine (Parkinson's patients) and the Department of Periodontology at the University of Health Sciences, Gulhane Faculty of Dentistry (Periodontitis patients and healthy controls).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Parkinson's Disease according to United Kingdom Parkinson's Disease Society Brain Bank Criteria (for study group). * Systemically healthy individuals (for control group). * Willingness to participate and sign informed consent. Exclusion Criteria: * Active smoking. * Comprehensive periodontal treatment within the last month. * Oral, respiratory, or digestive system diseases within the last 3 months. * Fewer than 16 natural teeth. * Use of full or removable partial dentures. * Dementia or inability to provide consent. * Serious active illnesses or substance abuse. * Antibiotic treatment within the last 3 months. * Probiotic use within the last month. * Radiotherapy/chemotherapy within the last 6 months. * Use of oral antiseptics within the last month. * Diabetes mellitus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation Parkinson disease periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (PD) Periodontal diseases Periodontitis

Contacts and locations

Locations

  • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği Fakültesi

    Ankara, 06010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.